Provided are a phi29 DNA polymerase mutant with increased thermo stability, a method for preparing the mutant, the use of the mutant, and a method for increasing the stability of the phi29 DNA polymerase.

A composition or matrix comprising a bacteriophage and nanofibrillar cellulose or a derivative thereof in a wet or dry state is disclosed.

Provided herein are compositions, systems, and methods for continuous and accumulative modification of a target site.

A phage and use thereof in soil remediation are disclosed. The phage YSZPK has been deposited at the China Center for Type Culture Collection on Aug. 1, 2018 under Accession No. CCTCC M 2018516, and its taxonomic designation is Pseudomonas aeruginosa and Klebsiella phage YSZPK. Biochar and the screened phage are combined and returned into contaminated soil to synergistically control and deeply track and inactivate transmission and spread of antibiotic resistance pathogenic bacteria and resistance genes in a soil-vegetable system. The combination of the biochar and the phage YSZPK not only clearly improves the functional stability of microbial community in the soil-vegetable system, but also significantly alleviates the dissemination of the antibiotic resistance pathogenic bacteria in the soil-vegetable system to prevent secondary pollution, thereby providing a new solution for biological remediation and control of farmland soil contaminated by antibiotic resistance pathogenic bacteria in China.

A phage dispensing system comprises a user interface, a phage treatment computing system, a phage laboratory, and a phage dispensing apparatus, including a dispensing kiosk. The user interface allows a treating physician to request testing of a patient sample by the phage laboratory to identify a phage mixture treatment. The phage computing system arranges shipping of the sample and provision of the identified phage mixture treatment to a dispensing apparatus located near the patient. The dispensing apparatus has a stock of phage vials which are used to prepare and dispense doses of the identified phage mixture treatment.

Provided are Cas9 enzymes that have mutations that enhance their properties, relative to un-mutated Cas9. The altered Cas9 enzymes exhibit i) an increased rate of spacer acquisition, or ii) increased cleavage efficiency of targets with NAG PAMs, or a combination of i) and ii). The altered Cas9 enzymes comprise an amino acid substitution of 1473 and K500 in a Streptococcus pyogenes or similar Cas9 enzyme. Also provided are polynucleotides, including expression vectors that encode the Cas9 enzymes, cells that contain the polynucleotides, and methods of making and using such cells. The disclosure includes tagging, or labelling bacteria, and for enhancing phage acquired immunity in bacteria, such as those used in industrial processes, including the food and beverage industry, such as the dairy industry. The food products are also included.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.

Various aspects and embodiments of the invention are directed to high-throughput phage-engineering methods and recombinant bacteriophages with tunable host ranges for controlling phage specificity.

The invention is directed to antibacterial compositions comprising bacteria modified to comprise phasmids engineered to deliver of CRISPR RNAs and methods for their use.

The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological compositions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections be the administration of an effective amount of compositions.